Symbols

BFRI

Biofrontera·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Stock Price Surged Significantly

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BFRI

Biofrontera Inc.

A biopharmaceutical company that develops and commercializes dermatological products

Industry

Pharmaceutical

Established Date

Listing Date

10/29/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.biofrontera-us.com

Security Type

Common stock

Office address

660 Main Street, 1st Floor, Woburn, MA 01801

Business

Introduction

Biofrontera Inc., was incorporated in Delaware in March 2015. The company is a US-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of skin diseases, especially diseases that cause skin damage due primarily to sun exposure. The company's licensed products focus on the treatment of actinic keratosis, a skin lesion that sometimes leads to skin cancer. The company also sells a topical antibiotic for the treatment of impetigo, a bacterial skin infection.

Company Financials

EPS

BFRI has released its 2025 Q4 earnings. EPS was reported at 0.48, versus the expected 0.18, beating expectations. The chart below visualizes how BFRI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BFRI has released its 2025 Q4 earnings report, with revenue of 17.10M, reflecting a YoY change of 36.16%, and net profit of 5.64M, showing a YoY change of 504.01%. The Sankey diagram below clearly presents BFRI's revenue sources and cost distribution.